pipette
ESEspañol

Maternal and Neonatal Outcomes Associated with Prenatal Prescription Stimulant Treatment Among Pregnant Individuals with Opioid Use Disorder

T. Reese, A. A. Leech, J. C. Phillippi, S. Patrick, E. McNeer, S. Loch, J. Young, A. von Horn, M. V. Shah, A. D. Wiese

PreprintReal-world use

In the authors' words

ABSTRACT Introduction: Clinicians and Medicaid programs must decide whether to continue prescription stimulants in pregnancies complicated by opioid use disorder (OUD), yet no safety evidence exists for this population and stimulant coverage is frequently restricted. We evaluated maternal and neonatal outcomes associated with prescription stimulant treatment during pregnancy among individuals with OUD, including those with co-occurring stimulant use disorder (StUD) and attention-deficit/hyperactivity disorder (ADHD). Methods: We conducted a retrospective cohort study of Medicaid-insured pregnant individuals in Tennessee (2010-2021) with OUD. Our exposure of interest was any prescription amphetamine- or methylphenidate-class stimulant overlapping pregnancy. The primary maternal outcome was overdose from delivery through 1 year postpartum; secondary outcomes included death, severe maternal morbidity and cardiovascular complications in the first 6 weeks postpartum. The primary neonatal outcome was preterm birth; secondary outcomes included low birth weight, NICU admission, neonatal opioid withdrawal syndrome (NOWS), and death. We used overlap weighting to estimate adjusted odds ratios (aORs) and predicted probabilities and evaluated effect modification by buprenorphine. Results: Among 12,327 pregnancies with OUD, 380 (3.1%) received prescription stimulants during pregnancy; stimulant treated individuals were slightly older and more likely to have mental health comorbidities. In adjusted analyses, stimulant treatment was not associated with postpartum overdose (aOR, 1.13; 95% CI, 0.61-2.08), preterm birth (aOR, 1.04; 95% CI, 0.74-1.46), cardiovascular complications, severe maternal morbidity, low birth weight, or NOWS. Odds of NICU admission were higher among stimulant exposed infants (aOR, 1.58; 95% CI, 1.17-2.14). Maternal and infant deaths were rare. In exploratory analyses, overdose odds were elevated among pregnancies receiving both stimulants and buprenorphine (P for interaction = .03) and the cardiovascular composite was elevated within the ADHD subgroup (aOR, 2.33; 95% CI, 1.13-4.82). Conclusions: These first OUD-specific estimates do not support routine discontinuation of clinically indicated stimulant therapy in pregnancy. Higher NICU admission among stimulant-exposed infants, unaccompanied by differences in preterm birth, low birth weight, gestational age, or NOWS, is more consistent with intensified surveillance than with neonatal harm. Two exploratory signals require replication before they can inform practice.

Main resultLimitation the authors admit

Appeared: Monday, November 16. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.12.26367944